Najib Ben Khaled, Christian Schulz, Marianna Alunni-Fabbroni, Kathrin Bronny, Leonie S Jochheim, Behnam Kalali, Osman Öcal, Max Seidensticker, Ignazio Piseddu, Stefan Enssle, Monika Karin, Julia S Schneider, Theresa Strasoldo-Graffemberg, Nadine Koch, Lukas Macke, Florian P Reiter, Christian M Lange, Yinghong Wang, Enrico N De Toni, Markus Gerhard, Julia Mayerle, Jens Ricke, Peter Malfertheiner
{"title":"幽门螺杆菌对肝细胞癌免疫检查点抑制的影响:一项多中心研究","authors":"Najib Ben Khaled, Christian Schulz, Marianna Alunni-Fabbroni, Kathrin Bronny, Leonie S Jochheim, Behnam Kalali, Osman Öcal, Max Seidensticker, Ignazio Piseddu, Stefan Enssle, Monika Karin, Julia S Schneider, Theresa Strasoldo-Graffemberg, Nadine Koch, Lukas Macke, Florian P Reiter, Christian M Lange, Yinghong Wang, Enrico N De Toni, Markus Gerhard, Julia Mayerle, Jens Ricke, Peter Malfertheiner","doi":"10.1159/000542847","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Immunomodulating effects of Helicobacter pylori (H. pylori) have been shown to inhibit antitumor immunity. Resistance to immune checkpoint inhibitor (ICI)-based therapies is common among patients with hepatocellular carcinoma (HCC). This study aimed to assess the effect of H. pylori on the outcomes of ICI in patients with HCC.</p><p><strong>Methods: </strong>We conducted a multicenter study in patients with HCC across a broad range of treatments. Patients received either ICI-based combination regimens or sorafenib-based therapy. H. pylori serostatus and virulence factors were determined and correlated with overall survival (OS), progression-free survival (PFS), and safety across the treatment modalities.</p><p><strong>Results: </strong>180 patients with HCC were included; among these, 64 were treated with ICI-based regimen and 116 with sorafenib-based regimen. In patients treated with ICI, median OS was shorter in H. pylori-positive patients (10.9 months in H. pylori-positive vs. 18.3 months; p = 0.0384). H. pylori positivity was associated with a shorter PFS in ICI recipients (3.9 months vs. 6.8 months, p = 0.0499). In patients treated with sorafenib, median OS was not shorter among H. pylori-positive patients (13.4 months in H. pylori-positive vs. 10.6 months; p = 0.3353). Immune-related adverse events and rates of gastrointestinal bleeding were comparable between H. pylori-positive and -negative patients.</p><p><strong>Conclusion: </strong>H. pylori seropositivity was linked to poorer outcomes in patients with HCC treated with ICI. This association was not observed among patients receiving sorafenib-based therapies.</p>","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"303-313"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study.\",\"authors\":\"Najib Ben Khaled, Christian Schulz, Marianna Alunni-Fabbroni, Kathrin Bronny, Leonie S Jochheim, Behnam Kalali, Osman Öcal, Max Seidensticker, Ignazio Piseddu, Stefan Enssle, Monika Karin, Julia S Schneider, Theresa Strasoldo-Graffemberg, Nadine Koch, Lukas Macke, Florian P Reiter, Christian M Lange, Yinghong Wang, Enrico N De Toni, Markus Gerhard, Julia Mayerle, Jens Ricke, Peter Malfertheiner\",\"doi\":\"10.1159/000542847\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Immunomodulating effects of Helicobacter pylori (H. pylori) have been shown to inhibit antitumor immunity. Resistance to immune checkpoint inhibitor (ICI)-based therapies is common among patients with hepatocellular carcinoma (HCC). This study aimed to assess the effect of H. pylori on the outcomes of ICI in patients with HCC.</p><p><strong>Methods: </strong>We conducted a multicenter study in patients with HCC across a broad range of treatments. Patients received either ICI-based combination regimens or sorafenib-based therapy. H. pylori serostatus and virulence factors were determined and correlated with overall survival (OS), progression-free survival (PFS), and safety across the treatment modalities.</p><p><strong>Results: </strong>180 patients with HCC were included; among these, 64 were treated with ICI-based regimen and 116 with sorafenib-based regimen. In patients treated with ICI, median OS was shorter in H. pylori-positive patients (10.9 months in H. pylori-positive vs. 18.3 months; p = 0.0384). H. pylori positivity was associated with a shorter PFS in ICI recipients (3.9 months vs. 6.8 months, p = 0.0499). In patients treated with sorafenib, median OS was not shorter among H. pylori-positive patients (13.4 months in H. pylori-positive vs. 10.6 months; p = 0.3353). Immune-related adverse events and rates of gastrointestinal bleeding were comparable between H. pylori-positive and -negative patients.</p><p><strong>Conclusion: </strong>H. pylori seropositivity was linked to poorer outcomes in patients with HCC treated with ICI. This association was not observed among patients receiving sorafenib-based therapies.</p>\",\"PeriodicalId\":11315,\"journal\":{\"name\":\"Digestion\",\"volume\":\" \",\"pages\":\"303-313\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Digestion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000542847\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542847","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
导读:幽门螺杆菌(Helicobacter pylori, H. pylori)具有抑制抗肿瘤免疫的免疫调节作用。对基于免疫检查点抑制剂(ICI)的治疗的耐药性在肝细胞癌(HCC)患者中很常见。本研究旨在评估幽门螺杆菌对HCC患者ICI预后的影响。方法:我们在HCC患者中进行了一项多中心研究,采用了广泛的治疗方法。患者接受以ci为基础的联合治疗方案或以索拉非尼为基础的治疗。确定了幽门螺杆菌血清状态和毒力因子,并将其与总生存期(OS)、无进展生存期(PFS)和各种治疗方式的安全性相关。结果:纳入HCC患者180例;其中,以ci为基础的方案治疗64例,以索拉非尼为基础的方案治疗116例。在接受ICI治疗的患者中,幽门螺杆菌阳性患者的中位生存期较短(幽门螺杆菌阳性患者10.9个月对18.3个月;P = 0.0384)。幽门螺杆菌阳性与ICI受者较短的PFS相关(3.9个月对6.8个月,p = 0.0499)。在接受索拉非尼治疗的患者中,幽门螺杆菌阳性患者的中位生存期并不短(幽门螺杆菌阳性患者为13.4个月对10.6个月;P = 0.3353)。免疫相关不良事件和胃肠道出血率在幽门螺杆菌阳性和阴性患者之间具有可比性。结论:幽门螺杆菌血清阳性与ICI治疗HCC患者预后较差有关。在接受以索拉非尼为基础的治疗的患者中未观察到这种关联。
Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study.
Introduction: Immunomodulating effects of Helicobacter pylori (H. pylori) have been shown to inhibit antitumor immunity. Resistance to immune checkpoint inhibitor (ICI)-based therapies is common among patients with hepatocellular carcinoma (HCC). This study aimed to assess the effect of H. pylori on the outcomes of ICI in patients with HCC.
Methods: We conducted a multicenter study in patients with HCC across a broad range of treatments. Patients received either ICI-based combination regimens or sorafenib-based therapy. H. pylori serostatus and virulence factors were determined and correlated with overall survival (OS), progression-free survival (PFS), and safety across the treatment modalities.
Results: 180 patients with HCC were included; among these, 64 were treated with ICI-based regimen and 116 with sorafenib-based regimen. In patients treated with ICI, median OS was shorter in H. pylori-positive patients (10.9 months in H. pylori-positive vs. 18.3 months; p = 0.0384). H. pylori positivity was associated with a shorter PFS in ICI recipients (3.9 months vs. 6.8 months, p = 0.0499). In patients treated with sorafenib, median OS was not shorter among H. pylori-positive patients (13.4 months in H. pylori-positive vs. 10.6 months; p = 0.3353). Immune-related adverse events and rates of gastrointestinal bleeding were comparable between H. pylori-positive and -negative patients.
Conclusion: H. pylori seropositivity was linked to poorer outcomes in patients with HCC treated with ICI. This association was not observed among patients receiving sorafenib-based therapies.
期刊介绍:
''Digestion'' concentrates on clinical research reports: in addition to editorials and reviews, the journal features sections on Stomach/Esophagus, Bowel, Neuro-Gastroenterology, Liver/Bile, Pancreas, Metabolism/Nutrition and Gastrointestinal Oncology. Papers cover physiology in humans, metabolic studies and clinical work on the etiology, diagnosis, and therapy of human diseases. It is thus especially cut out for gastroenterologists employed in hospitals and outpatient units. Moreover, the journal''s coverage of studies on the metabolism and effects of therapeutic drugs carries considerable value for clinicians and investigators beyond the immediate field of gastroenterology.